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PARDIOVASCULAR GENOMIC MEDICINE
edefining Heart Failure
he Utility of Genomics
ark P. Donahue, MD, MHS,*† Douglas A. Marchuk, PHD,‡ Howard A. Rockman, MD*‡
urham, North Carolina
In this era of genomics, new technologies and the information that they generate have a wide
range of potential applications to heart failure. Though there has not been widespread
practical use of genomic information in everyday practice, there are many examples of how
this information is beginning to transform the way we look at disease states in terms of
diagnosis, prognosis, and treatment. The experience of oncology and other fields helps inform
the heart failure field of not only the use of this information in investigating diagnosis,
prognosis, and treatment response, but the reciprocal nature of this information. This
information can be clinically useful (for instance, predicting treatment response) as well as
further drive laboratory investigation (teasing out the biological pathways in non-responders
to treatment can be a focus of new drug discovery); this is the essence of translational
medicine. We believe that this is a good time to review where new technologies and
information they generate can be placed into our classic understanding of heart failure: that
is how we might redefine cardiomyopathy given our new information. Here we will review
genomic evidence to date and how it can and may be considered in the evaluation and
management of cardiomyopathies. (J Am Coll Cardiol 2006;48:1289–98) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.062American College of Cardiology Foundation
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fEDEFINING HEART FAILURE:
HE UTILITY OF GENOMICS
n this era of genomics, new technologies and the informa-
ion that they generate have a wide range of potential
pplications to heart failure. Genomics is a term broadly
sed that was “born from a marriage of molecular and cell
iology with classical genetics and is fostered by computa-
ional science” (1). Here we use the term genomics to
nclude the entire complement of genes and their resultant
essenger RNA. The arenas of proteomics and biological
arkers, such as brain natriuretic peptide (BNP), have
emonstrated clinical utility; however, a discussion of pro-
eomics is beyond the scope of this review. The use of
enomic information has long held the promise of trans-
orming clinical practice. A perception of a slow or no
ransformation has largely been fueled by a disconnection
etween media and scientific timelines. Though there has
ot been widespread practical use of genomic information in
veryday practice, there are many examples of how this
nformation is beginning to transform the way we look at
isease states in terms of diagnosis, prognosis, and treat-
ent. Oncology has been at the forefront of applied
enomics. This has been driven in large part by the wide
vailability of biological samples and the use of microarray
echnology to assess gene expression. The number of studies
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ccepted May 29, 2006.sing microarray technology for subclassification of tumors
diagnosis and prognosis) and to evaluate the utility of
herapy (directing treatment) has increased greatly in the
ast 5 years. In addition, genetic testing in familial cancers
uch as breast cancer and ovarian cancer (the BRCA 1 and
genes) and colon cancer are used routinely in practice. In
ddition to the basic and clinical science, there are great
omplexities surrounding such genetic information and any
pecific patient; these include disease variability, genetic
ounseling, and the potential for social and economic
iscrimination (i.e., insurance). The experience of oncology
nd other fields helps inform the heart failure field of not
nly the use of this information in investigating diagnosis,
rognosis, and treatment response, but the reciprocal nature
f this information. This information can be clinically useful
for instance disease prediction) as well as further drive
aboratory investigation (teasing out the biological pathways
n non-responders to treatment can be a focus of new drug
iscovery); this is the essence of translational medicine. We
elieve that this is a good time to review where new
echnologies and information they generate can be placed
nto our classic understanding of heart failure: that is, how
e might redefine cardiomyopathy given our new informa-
ion. Here we will review genomic evidence to date and how
t can and may be considered in the evaluation and man-
gement of cardiomyopathies.
lear clinical problem. Heart failure is a major public
ealth burden in the U.S., causing approximately 200,000
eaths per year (2). Approximately 3 million people have
hronic heart failure, with more than 400,000 new heart
ailure diagnoses annually (2). Heart failure is the most
ommon Medicare diagnosis-related group (3), and the
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Genomics and Heart Failure October 3, 2006:1289–98umber of hospitalizations for heart failure as a primary or
econdary diagnosis increased by approximately 50% be-
ween 1985 and 1995 (4). In the outpatient setting, heart
ailure is the second most common cardiovascular diagnosis,
urpassed only by hypertension (5). This enormous clinical
urden has a staggering economic impact costing the U.S.
conomy $38.1 billion dollars, or 5.4% of total health care
xpenditures for 1991 (5). Approximately 80% of patients
ith heart failure are older than 65 years (5), and 92% of the
ortality attributed to heart failure occurs in this age group
3). This disease burden will only increase, potentially
oubling the number of heart failure patients (6) because the
umber of people over 65 years is expected to be 70 million
y 2030 (7). Thus, there is considerable morbidity and
ortality associated with heart failure, despite innumerable
athophysiologic discoveries and therapeutic advances over
he past 2 decades. The 2 ways to approach this problem are
o further advance the field with new therapeutics (both for
rimary and secondary prevention), which will require new
nsights into pathophysiology, and to stratify those individ-
als currently receiving therapy (into responders and non-
esponders). Both of these areas can be advanced by
enomics.
henotyping. The disease heart failure is, in reality, a
linical syndrome that results from many etiologies and
ulminates in an inability for the heart to provide adequate
ow to meet the metabolic needs of the body. Heart failure
an occur in the setting of either normal or abnormal
ystolic function. Diastolic heart failure (heart failure with
ormal systolic function) and hypertrophic obstructive car-
iomyopathy are also causes of the syndrome of heart
ailure. For the purposes of this review, we focus on heart
ailure in the setting of abnormal cardiac function or
ardiomyopathy. Although the causes of cardiomyopathy
unnel into common late stage pathways (and thus have
imilar/identical clinical presentations), the origins of the
ardiac dysfunction and the timeline to the onset of the
yndrome are varied. Whereas the origins of some cardio-
yopathies are relatively clear, for example Chaga’s disease
r anthracycline exposure, others that fall under general
esignations such as dilated cardiomyopathy (DCM) are
ikely to represent many diseases (with only our poor ability
o subclassify them preventing this from being obvious).
urrently staging systems for heart failure rely largely on
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
ACE  angiotensin-converting enzyme
BNP  brain natriuretic peptide
DCM  dilated cardiomyopathy
HCM  hypertrophic cardiomyopathy
ICM  ischemic cardiomyopathy
LVAD  left ventricular assist devicelinical characteristics and imaging for diagnosis. Histori-
A
fally, groups such as the World Health Organization have
ttempted to formalize a classification for cardiomyopathies
8). Although these early attempts at classification began to
ease out the many different causes of cardiomyopathy, they
ocus on the dominant pathophysiology and some etiologic/
athogenetic factors. Recently, newer attempts have been
ade to both classify and stage cardiomyopathy. These
ttempts build upon prior work with an emphasis on
ecognition of the early stages of cardiomyopathy and an
mphasis on precise determination of etiology (9). Similarly
he newest American College of Cardiology/American
eart Association (ACC/AHA) guidelines for chronic
eart failure (10) take a “new approach” to the classification
f heart failure, one that emphasizes both the development
nd progression of disease. Table 1 summarizes staging of
ardiomyopathy by current guidelines. Though recognition
f early stages of disease may assist in prevention and
herapy, the etiologic classification, in a majority of cases, at
his time does not lead to specific upstream interventions.
rue prevention will come when specific etiologies are
nderstood. In addition, cardiomyopathies that appear to
ave a clear origin, such as ischemic cardiomyopathy
ICM), can have highly varied disease timelines, a process
ediated by a variety of factors.
Traditional management of heart failure has focused on
he management of individuals with symptomatic disease
stages C and D of the ACC/AHA guidelines). The heart
ailure community has not traditionally focused on the
dentification of asymptomatic disease (or pre-structural/
re-symptomatic disease). Newer technologies may assist in
dentifying those in stage A who will progress to have
tructural disease and those in stage B who will develop
ymptoms. Such earlier identification will allow more fo-
used preventative measures and treatments, individualized
o that the number of patients needed to treat (to prevent a
linical event) can be reduced.
ENE EXPRESSION
he technology to quantitate and monitor gene expression
as exploded in that past 10 years since the microarray was
opularized by the group at Stanford headed by Pat Brown
nd David Botstein (11). DNA microarrays allow the
imultaneous measurement of the level of transcription of
housands of genes. There are several types of arrays; some
able 1. Progression of Cardiomyopathy
At Risk for
Cardiomyopathy
or Heart Failure
(No Structural
Disease)
Asymptomatic
Cardiomyopathy
(Structural
Heart Disease)
Symptomatic
Cardiomyopathy
tage A* Stage B* Stage C and stage D*
tage 1† Stage 2† Stage 3†
American College of Cardiology/American Heart Association Diagnosis and Man-
gement of Chronic Heart Failure in the Adult (10); †Heart Failure Society of
merica Definition, Classification, and Staging of Adult Cardiomyopathies: Proposal
or Revision (9).
a
d
a
g
m
o
i
r
p
a
(
a
s
t
f
g
t
c
d
e
d
t
o
f
A
t
e
t
(
c
b
v
e
d
t
i
t
p
t
t
D
m
o
s
f
(
a
o
i
o
o
o
l
h
a
d
c
t
h
o
p
n
w
n
g
v
t
t
e
D
t
c
r
s
8
a
t
i
g
D
h
s
h
a
c
r
g
c
t
o
fi
(
a
G
e
p
p
4
t
s
c
t
u
w
u
r
g
s
i
i
1291JACC Vol. 48, No. 7, 2006 Donahue et al.
October 3, 2006:1289–98 Genomics and Heart Failurere available commercially, and others can be custom made
epending on the particular research interest. Commercially
vailable microarrays are populated by a standard set of
enes derived from the human genome project. Custom
icroarrays can contain a large number of genes depending
n the research interest. This technology has been powerful
n stimulating thinking about disease classification and the
eciprocal flow of information.
The use of gene expression data has already resulted in a
alpable effect in the field of oncology. Initially, microarrays
ssisted in tumor classification as an adjunct to histology
12,13). The technology then showed utility in chemother-
py response in diffuse large B-cell lymphoma (14) and
urvival in breast cancer (15). In a similar fashion, we know
hat histologic classification of non-ICM has a poor yield
or an etiologic diagnosis, so it is possible that newer
enomic technologies will allow for a similar subclassifica-
ion of disease states. Such staging would allow for a better
linical understanding and application of this technology to
iagnosis, prognosis, and therapeutics. In addition, gene
xpression signatures have identified patterns of pathway
eregulation across human cancers that not only elucidate
he biology of the process but also allow for the development
f more targeted therapy (16). Two practical examples come
rom the transplant literature. The CARGO (Cardiac
llograft Rejection Gene Expression Observational) Inves-
igators used microarray technology to develop an 11-gene
xpression profile with a high negative predictive value for
he presence of rejection in patients after cardiac transplant
17). An example of the reciprocal flow of information
omes from the renal transplant literature (18) where
iopsies of individuals with acute rejection were investigated
ia gene expression analysis. Though there were no differ-
nces on conventional histology, there were considerable
ifferences in gene expression patterns, which suggested
hat additional histologic staining would allow previously
ndistinguishable samples to be accurately subtyped. Thus,
he gene expression information helped redefine the ap-
roach to rejection with conventional histology. We believe
hat genomics will help redefine aspects of etiology, initia-
ion, and progression of heart failure.
iscovery science. Investigators have used both the com-
ercially available Affymetrix (Santa Clara, California)
ligonucleotide arrays and as well as custom cDNA arrays to
tudy cardiomyopathy. A custom chip with a cardiovascular
ocus, called the Cardiochip, was developed by Barrans et al.
19). It contains 10,368 different cardiovascular-based genes
nd was utilized is several studies to be highlighted. Much
f the current literature regarding the use of gene expression
n the investigation of cardiomyopathy falls in the category
f discovery science. Discovery science involves using meth-
ds, such as gene expression, to find underlying mechanisms
f disease that were not previously known. Studies to date
ook broadly in small cohorts at failing versus non-failing
earts and the myocardium pre- and post-left ventricular
ssist device (LVAD). Given the requirement for myocar- lial tissue specimens, these studies almost uniformly use
ardiac explants from individuals undergoing transplant and
he control (or non-failing) hearts from rejected donor
earts. The cases, therefore, represent end-stage cardiomy-
pathy (stage D or 3). Table 2 summarizes these discovery
rojects (20–30). These studies largely center on finding
ew pathways in the hope that better disease understanding
ill ultimately lead to improvements in diagnostics, prog-
ostics, and drug discovery. These studies find hundreds of
enes that are differentially expressed and implicating
aried pathways including calcium signaling, energy me-
abolism, apoptotic pathways, stress response, signal
ransduction, and the maintenance of the cytoskeletal and
xtracellular matrix.
isease classification and prognosis. Contained within
hese discovery projects are areas of potential clinical appli-
ation, such as cardiomyopathy classification and predicting
esponse to treatment. Two studies featured in Table 2 were
uggestive that disease classification is possible. In 1 study of
individuals with DCM, patterns in individuals with
lcohol-related cardiomyopathy and familial cardiomyopa-
hy were significantly different (22). In another study of
ndividuals receiving an LVAD, the expression data segre-
ated into 2 distinct groupings corresponding to ICM and
CM (27). In addition to these discovery projects, there
ave been some early attempts at disease classification. One
tudy demonstrated that individuals with advanced stage
ypertrophic cardiomyopathy (HCM) and DCM had 621
nd 399 genes, respectively, up-regulated compared with
ontrol subjects and 236 and 51 genes, respectively, down-
egulated. Of these figures, only 48% of the up-regulated
enes and 22% of the down-regulated genes were in
ommon. Though these entities are readily discernable on
he clinical level, these findings lend credence to the concept
f the using of gene expression for cardiomyopathy classi-
cation. Another case in point is the study by Kittleson et al.
31) who sought to use the gene expression information as
diagnostic to predict (or classify) cardiomyopathy etiology.
ene expression profiles were obtained on 25 patients with
nd-stage cardiomyopathy (10 ICM and 15 DCM), 16
atients post-LVAD (3 ischemic and 13 DCM), and 7
atients with newly diagnosed cardiomyopathy (3 ICM and
DCM). An etiology prediction profile was formulated and
ested; the authors report an 89% sensitivity and 89%
pecificity for predicting an ischemic versus non-ischemic
lassification of cardiomyopathy specimens. In addition to
he potential in diagnostics, there are potential prognostic
ses. One study of gene expression pre- and post-LVAD
as supportive of the potential for gene expression to be
sed in conjunction with clinical parameters to predict
ecovery post-LVAD (27). Using clinical and tissue-based
ene expression data appears promising in these early
tudies of disease. In contrast with discovery science, which
nvestigates small numbers of patients, such studies target-
ng disease classification as well as prognosis will require
arger cohorts to demonstrate their clinical utility.
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Genomics and Heart Failure October 3, 2006:1289–98The enthusiasm for gene expression technology must be
empered, however, as there are many variabilities and
ractical matters to consider. Some studies suggest that gene
xpression can vary by site of tissue acquisition right
entricle versus left ventricle within an individual (24,32).
nother study demonstrated the critical need to account for
linical variables as investigators demonstrated that even
lementary clinical variables such as age and gender can have
significant influence on gene expression (33). There will
lso be a need to account for other comorbidities and
odifying elements, such as medications; thus, high-fidelity
able 2. Discovery Projects
Comparison Subjects P
ailing versus non-failing 2 cases (1 ICM and 1 DCM)
2 control cases
Affymetrix
ailing versus non-failing 7 cases (DCM)
5 control cases
Cardiochip
ailing versus non-failing 8 cases (DCM)
7 control cases
Affymetrix
ailing versus non-failing 10 cases (DCM) Custom ar
4 control cases
ailing versus non-failing 9 cases (5 ICM and 4 DCM)
1 control case
Affymetrix
ailing versus non-failing 6 cases (DCM)
5 control cases
Affymetrix
ailing versus non-failing 5 cases (DCM)
5 control cases
Custom ar
apoptot
re- and post-left
ventricular assist device
6 cases (3 DCM and 3 ICM) Affymetrix
re- and post-left
ventricular assist device
7 cases (DCM) Affymetrix
re- and post-left
ventricular assist device
19 cases (8 DCM and 11 ICM) Affymetrix
CM and DCM versus
non-failing
3 DCM
2 HCM
3 control cases
Cardiochip
CM  dilated cardiomyopathy; HCM  hypertrophic cardiomyopathy; ICM  ilinical information will be an essential partner in genomic sesearch. This integration of clinical and genomic informa-
ion into predictive models will require innovative statistical
pproaches. In addition, as a practical matter, these gene
xpression studies require myocardial tissue, which is not
eadily accessible. Most of the discovery studies to date used
issue from myocardial explants. Some studies have em-
loyed the use of tissue from myocardial biopsies, though
hat approach raises potential issues with the site of tissue
cquisition and need for RNA amplification. Given that
eart failure is a systemic process, sampling RNA from
irculating blood cells may hold some promise, but, in a
m Findings Reference
6800 Alterations of expression of cytoskeletal and
myofibrillar genes, genes encoding stress
proteins, and genes involved in metabolism,
protein synthesis, and protein degradation
(20)
tom array) Up-regulation of genes for atrial natriuretic
peptide, sarcomeric and cytoskeletal
proteins, stress proteins, and transcription/
translation regulators
(21)
Down-regulation of genes regulating calcium
signaling pathways
6800 103 differentially expressed genes with most
prominent being atrial natriuretic factor
and brain natriuretic peptide
(22)
364 differentially expressed genes (23)
Up-regulation being most prominent in genes
for energy pathways, muscle contraction,
electron transport, and intracellular
signaling
Down-regulation was most prominent in
genes for cell cycle control
-U95A 95 differentially expressed genes with notable
up-regulation of atrial natriuretic peptide
and brain natriuretic peptide
(24)
Prominent pathways up-regulated include cell
signaling and muscle contraction
-U133A 165 differentially expressed genes, the most
prominent being structural and metabolic
genes
(25)
r
hways
Differentially expressed genes in apoptotic
pathways
(26)
6800 530 differentially expressed genes (295 up and
235 down) with prominent changes in
genes for metabolism
(27)
-U133A 179 differentially expressed genes (130 up and
49 down
(28)
There was prominent up-regulation in nitric
oxide pathways and down-regulation of
inflammatory genes
-U133A 107 differentially regulated genes (85 up and
22 down)
(29)
Prominent was the up-regulation of genes
regulating vascular networks and
down-regulation of genes regulating
myocyte hypertrophy
tom array) Multiple genes and pathways up- and
down-regulated some common to DCM
and HCM some distinct to each
(30)
ic cardiomyopathy.latfor
Hu
(cus
Hu
rays
HG
HG
ray fo
ic pat
Hu
HG
HG
(cusimilar fashion to myocardial samples, prior studies have
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October 3, 2006:1289–98 Genomics and Heart Failureemonstrated variation in gene expression from human
lood depending on age, gender, and diurnal patterns (34).
In summary, microarray technology and its ability to assay
housands of genes simultaneously is beginning to show its
otential in discovery science. Though there are also some
romising areas such as a better defined cardiomyopathy
lassification (diagnostics) and possibly the ability to predict
ecovery after placement of a LVAD (prognostics), there is
o evidence that these types of assays are ready for general
linical use. As we are able to subclassify cardiomyopathies,
e may be able to better understand their varied pathophys-
ology and as a result develop not only better diagnostics and
rognostics but also novel therapeutic interventions. As the
otential of this technology becomes evident, the clinical
esearch enterprise needs to address where, when, and how
o test this new, powerful (and at times unwieldy) informa-
ion.
ENETICS
edical genetics is predicated on the concept of genetic
ariation (polymorphism) resulting in disease. Medical ge-
etics has traditionally focused on diseases that can be
racked through families. These familial disorders, such as
untington’s disease, are the result of a single gene defect
nd are often termed single-gene or monogenetic disorders.
ommon diseases—such as hypertension and coronary
rtery disease—are not caused by a single gene. These are
ermed complex diseases, where there are contributions of a
ariety of genes as well as environmental factors. Although
genetic variant may have a large contribution and directly
ause the disease (causative gene), there also may be a
odest contribution producing the disease when coupled
ith other factors such as environmental exposure (a sus-
eptibility gene), or there may be a minor contribution that
epends on the presence of other genetic and environmental
actors (a modifier gene). Sometimes the differences be-
ween these categories can be blurred. For instance, a
amilial cardiomyopathy may track through a pedigree
anifesting variably (often referred to as variable pen-
trance). The gene (in this case for familial cardiomyopa-
hy), however, may in reality be a susceptibility gene that
nly becomes apparent after an exposure to some environ-
ental influence. The critical point is that genetics influ-
nce the variability in the presentation, course, and outcome
f disease in a variety of ways; these influences can occur at
he origin of the disease process as well as any time point
long the disease process.
amilial cardiomyopathy: genes of clear causation. Mo-
ecular genetics has provided the most insight with im-
roved classification of idiopathic cardiomyopathies. As
tated earlier, the idiopathic cardiomyopathies were origi-
ally named as such when there was no clear antecedent
vent such as ischemia. It has been estimated that 35% of
ndividuals with an idiopathic DCM will have inherited
isease or familial DCM (35). Among these individuals, Chere are some distinct phenotypes including groups with
ardiomyopathy and conduction disease and cardiomyopa-
hy with associated muscle disease (35). The most common
ode of transmission in familial DCM is autosomal dom-
nant (56%) (36). As molecular geneticists had success in
apping the disease genes in some of these diseased
amilies, a number of things emerged. One concept was that
ultiple genes (or alleles) can cause cardiomyopathy (allelic
eterogeneity). A second is that within a gene multiple
ifferent mutations can cause cardiomyopathy (locus heter-
geneity). Third and adding greatly to the complexity is that
istinct mutations in the same gene can cause different types
f cardiomyopathy. For instance, mutations in cardiac
eta-myosin heavy chain or cardiac troponin T can result in
phenotype of DCM or HCM (37,38) depending on the
ocation of the mutation in relationship to the contractile
pparatus. At the level of the myocyte, some mutations
ppear to effect the sarcomere and the ability to generate
orce while others the cytoskeleton and the ability to
ransmit force. Whereas many of the genetic variants
ausing DCM are from defects in the cytoskeleton, other
athways may be affected such as changes in calcium
ignaling (38–40). Given that we are at only the beginning
f our understanding of the causes of familial DCM, then it
hould come as no great surprise that little is known about
he presentation and course of the disease for which the
enetic defect is known. The natural history of familial
CM is not known with the exception of some rare cases
lamin A/C [41]), and mutation-specific interventions be-
ond standard heart failure therapy and genetic counseling
o not exist (42). Table 3 depicts many of the genes
mplicated in cardiomyopathy, and it is designed to illustrate
he wide array of genes that have been discovered to date to
e involved in the development of idiopathic DCM
37,40,43–54).
The discovery of causative mutations has important
mplications for diagnosis, prognosis, and intervention.
uch previous discovery work has been accomplished
hrough linkage analysis of human pedigrees. The use of
able 3. Heterogeneity in the Genetics of Dilated
ardiomyopathy
Gene Function Reference
eta-myosin heavy chain Force generation (37)
itin Force transmission (43)
lpha-tropomyosin Force generation (44)
amin A/C Nuclear membrane protein (45)
elta sarcoglycan Force transmission (46)
hospholamban Calcium cycling (40)
ctin Force generation (47)
esmin Force transmission (48)
etavinculin Force transmission (49)
ardiac troponin I Force generation (50)
ardiac troponin C Force generation (51)
Cap (titin can/telethonin) Force transmission (52)
ypher/ZASP Force transmission (53)
uscle LIM protein Force transmission (54)
ardiac troponin T Force generation (51)
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Genomics and Heart Failure October 3, 2006:1289–98odel systems, such as the mouse, show promise for
dentifying novel genes that may cause human cardiomyop-
thy (55) and more recently even simpler model systems,
uch as the drosophila, show similar utility (56). As the
echanisms underlying these cardiomyopathies are ex-
lored and understood, the potential for novel and earlier
nterventions exist. Given the current complexity of the
eld, no clinically useful genetic testing is available. Tech-
ology, however, continues to rapidly improve; low-density
NA microarrays (57) have demonstrated some preliminary
uccess in screening for mutations in HCM, and advances
uch as this could allow simultaneous diagnostic testing of
housands of genetic variants. Once this diagnosis is possi-
le, then the mutation-specific disease course (prognosis)
an be better understood and disease-specific interventions
tilized (both novel therapeutics and existing medications
sed earlier).
odifier genes. In contrast with genes that cause cardio-
yopathy, we are also interested in those genes that modify
he presentation, course, and outcome of a cardiomyopathy;
e refer to these genes in this regard as modifier genes. A
odifier may exert its effect through a variety of mecha-
isms including gene– gene interactions and gene–
nvironment interaction. We use environment as an all-
ncompassing term to mean any factor external to the
isease process that may alter the disease process; the most
nfluential of these items in medicine are medications.
odifier genes will most often be polymorphisms, a term
hat means a mutation (often a single-base change) occur-
ing at a frequency higher than 1% of the population. We
re only beginning to understand modifier genes. Often
hese genetic variants (polymorphisms) do not exert a large
henotypic effect, but taken as a composite they exert a
ignificant effect. There are several examples in the cardio-
yopathy literature of modifier genes: how they influence
omorbidities (such as arrhythmia), drug effect (pharmaco-
enetics), each other (gene–gene interactions), and survival.
o date, most of the genes in the literature that have been
nvestigated in these association studies have been candidate
enes chosen because of their biological plausibility. Less
iased methods have also been employed using model
ystems such as the mouse to isolate novel modifier genes
58,59). Here we discuss some notable modifier genes from
he literature.
nfluence on comorbidities. Arrhythmia and sudden car-
iac death are comorbidities significant in cardiomyopathy.
lthough the implantable cardioverter-defibrillator has be-
ome the standard of care in the management of cardiomy-
pathy, there has been little advance in the understanding of
ho is at most risk of a lethal arrhythmia. Much in the way
hat molecular biology has enhanced the understanding of
he long QT syndromes, there exists potential for similar
nderstanding (and subsequent risk stratification) in pa-
ients with cardiomyopathy. The syndromes caused by
bnormalities in cardiac ion channels discovered through
olecular biology have been termed channelopathies. A aene that has been studied extensively, SCN5A, encodes
lpha subunits of the cardiac sodium channel (60), and
utations in the gene have been associated with several rare
rrhythmias. Family-based studies have implicated muta-
ions in SCN5A to syndromes of cardiomyopathy and atrial
rrhythmias. In addition, a polymorphism in the SCN5A
ene, which is common in individuals of West African and
aribbean descent, is associated with an increased risk of
entricular arrhythmia (61–63). These studies may assist in
etter subclassification of cardiomyopathy (here with regard
o predisposition to arrhythmia). Indeed, future studies may
mplicate specific genes that will constitute modifier chan-
elopathies (i.e., channelopathies resulting in either atrial or
entricular arrhythmias that modify the course and outcome
f cardiomyopathy). These studies suggest such genes could
etermine the use of pharmacologic or device therapy for
he treatment of arrhythmias in the setting of cardiomyop-
thy in the future.
harmacogenetics. The most promising area for clinical
pplication for modifier genes is in the arena of pharma-
ogenomics. As a simple example, let’s take a hypothetical
rug A that blocks a receptor B and is metabolized in the
iver by cytochrome C. If an individual has a polymorphism
n receptor A that does not allow the drug to block
ffectively at normal levels, then the drug will likely not be
s effective in that individual. If the same individual has a
olymorphism in cytochrome C that leads to slower metab-
lism then this may increase the drug level relative to
eceptor B, and subsequently the effect of drug A may
elatively increase. In contrast, if a polymorphism exists that
eads to faster metabolism, then the drug concentration will
e even lower, and drug A will have even less of an ability
o block receptor B. There are already several examples in
he literature with respect to chemotherapeutic agents and
arfarin metabolism. Differential response to pharmaco-
herapy in patients with heart failure was the origin of
-HeFT (African American Heart Failure Trial), which
emonstrated a survival benefit of a fixed dose combination
f isosorbide dinitrate and hydralazine (64). Although the
iological specifics for the benefit of this medication strategy
n African-American patients are not entirely clear, such
ndings suggest the role of underlying genetic variation.
uch studies provide a small step toward the ultimate goal of
ndividualizing therapy—finding the right drug for the right
atient.
Angiotensin-converting enzyme (ACE) inhibitors and
eta-blockers are standard treatments for patients with heart
ailure (65) and both have been investigated in terms of
harmacogenetics. Genetic variation in the beta1 adrenergic
eceptor has been well characterized (66). The Arg389Gly
olymorphism in the beta1 receptor has been shown to cause
ifferential stimulation with respect to agonists and thus a
ifferent response to blockade (66). Animal models confirm
differential physiologic response to beta-blocker based on
enotype and suggest that clinical outcomes in humans may
lso be affected (66). Beta1 adrenergic receptor variation (the
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October 3, 2006:1289–98 Genomics and Heart Failurerg389Gly) has been associated with exercise capacity in
atients with heart failure (67) and differential receptor signal-
ng. A retrospective study found an improvement in myocar-
ial ejection fraction in those individuals treated with carvedilol
ho carried the Arg389 variant (66). Observations of differ-
ntial physiological and pathophysiological responses based on
genotype can inform future clinical studies with the idea of
solating responders from non-responders.
Polymorphisms in the ACE pathway may also be revealing.
n a population of chronic heart failure patients, the ACEDD
olymorphism was significantly associated with death or the
eed for transplant when compared with II or ID genotypes,
ut those with ACE DD treated with beta-blockers had
ignificantly improved survival compared with those not on
eta-blockers (68). This observation was not seen in either the
I or ID group. In a similar study, patients with the DD
olymorphism had worse outcomes on low-dose ACE inhib-
tor therapy compared with high dose (69), and the regiment of
igh-dose ACE inhibitors and beta-blockers had the greatest
mpact on transplant-free survival in those with the DD
ariant. These studies suggest a differential clinical response to
tandard heart failure therapy based on information on the
CE I/D variant. These preliminary studies of genetic varia-
ion in the beta receptor and ACE pathways suggest that such
enetic information in the future may assist in the choice of
ype and dose of medication for patients with heart failure.
here are many genetic variants that influence the efficacy of
harmacotherapy by impacting some aspect of absorption,
etabolism, or physiologic effect of a drug; many of these have
et to be elucidated. Table 4 illustrates some examples of the
otential of pharmacogenetics and its current level of evidence
able 4. Pharmacotherapy and Examples of the Potential of Pha
Drug Genetic Variant
CE inhibitors ACE
insertion/deletion (ACE II/DD)
DD variant is
improved tr
with higher
eta-blockers ACE II/DD Association wi
individuals w
Arg389Gly Beta-1
adrenergic receptor
Arg389 was as
treated with
Gly389 individ
medications
Ser49Gly Beta-1
adrenergic receptor
Gly49 was asso
characterstic
Ser49 individu
medications
Gln27Glu Beta-2
adrenergic receptor
Gln27 was ass
those treated
Cytochrome P450 2D6 (CYP2D6) Influences dru
uthors assessment of levels of evidence: A  evidence for use in clinical practice; B
 studies suggestive of a differential pharmacologic effect dependent upon genoty
ACE  angiotensin-converting enzyme.66,68–72).
*
tene–gene interactions. Given the complexity of biolog-
cal systems, it can certainly be appreciated that for any
iven disease there are likely numerous genetic variants
xerting an influence. That being said, there are very few
tudies that investigate gene-gene interactions. One such
tudy in the heart failure literature investigated the
rg389Gly variant of the beta1 adrenergic receptor in
onjunction with an alpha2 adrenergic polymorphism (a
-base pair deletion at position 322-325, termed Del322-
25) that is common in African American patients (76).
lthough the Arg389Gly was not predictive of heart failure
y itself, the study found that those individuals homozygous
or the Del322-325 in conjunction with Arg389 variant had
etween a 3.87 (for heterozygotes) and 10.11 (for homozy-
otes) risk for heart failure. Given the prevalence of the
el322-325 allele in African Americans compared with
hites, these findings reach statistical significance (for the
iven sample size) in the African American cohort.
urvival. Prognostic markers are valuable clinical tools for
atients with heart failure because they may identify indi-
iduals that require earlier and more aggressive intervention.
everal polymorphisms have been implicated in retrospec-
genetics
Potential Implications
Level of Evidence
(Author’s Assessment)
iated with higher levels of ACE (70) and
nt-free survival in DD individuals treated
of ACE inhibitors (69)
B
proved transplant-free survival in those
D variant treated with beta-blockers (68)
B
ed with improved ejection fraction in those
prolol (71) and carvedilol (66)
B
equired greater titration of heart failure
d with improved ventricular remodeling C
quired greater titration of heart failure
and had a poorer beta-blocker response (73)
d with improvement in ejection fraction in
carvedilol (74)
C
ls of metoprolol (72) and carvedilol (75) C; pharmacokinetic
differences have not
been associated with
clinical differences
nsistent findings that require clinically relevant studies for defining use in practice;
uire further studies.
able 5. Examples of Genes Associated With Survival in Heart
ailure
Gene (Variant)
Adjusted
Relative Risk*
Population
Frequency Reference
eta-2 adrenergic receptor
(Ile164)
4.81 (2.0–11.5) 4% (77)
denosine monophosphate
deaminase (AMPD1)
4.65 (1.48–14.66) 16% (78)rmaco
assoc
anspla
doses
th im
ith D
sociat
meto
uals r
(72)
ciate
s (71)
als re
(72)
ociate
with
g leve
 coStudy outcome via Cox proportional hazards modeling for time to death or cardiac
ransplant.
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Genomics and Heart Failure October 3, 2006:1289–98ive studies to be associated with a poorer prognosis in
atients with cardiomyopathy (Table 5) (77,78). The stud-
es suggest that these markers could be used for risk
tratification; however, despite a strong association, there
as been no subsequent literature validating the findings.
nce validated, the association could be tested in clinical
are, for instance, should individuals with variants sugges-
ive of poorer outcomes be treated earlier with more
ggressive existing therapies or listed for transplant earlier.
Taken as a composite, it may be possible in the future to
enerate patient-specific data of heart-failure-related genes
perhaps through a panel of genes on a microarray) that will
rofile genes of diagnostic, prognostic, and therapeutic
mportance. The current landscape of genetics in this field
oes not support the routine use of any genetic tests in the
anagement of cardiomyopathy due to systolic dysfunction.
ONCLUSIONS
ew high-throughput technologies and the information
hey generate have promise for clinical use in cardiomyop-
thy and can be integrated into framework of heart failure
anagement (Fig. 1). While these technologies generated
n early exuberance of their immediate potential, the reality
s that their impact will likely only be realized over time.
here is no current evidence supporting the routine clinical
se of genomic information in the care of patients with
ardiomyopathy. Genomic information is similar to any
ther piece of clinical or laboratory information, whether
hat information is weight or a BNP level; testing this
nformation to learn where it should be placed in the context
f improving patient care is the critical step. An efficient
igure 1. Integrating genomic evidence into the management of cardiomyo
his figure illustrates the potential points of integration of genomic inforystem that takes newly discovered genetic information,laces it into a clinical context, and then takes appropriate
ext steps to study this material on the larger scale, a scale
hat is generalizable to larger populations, will provide great
dvances to the field.
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